Actualités et vidéos - VERACYTE INC.

Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing detected cancer in patients treated for muscle-invasive bladder cancer (MIBC) with more accuracy than ddPCR-based blood testing and earlier compared to standard imaging. The findings, from the large, independent, multicenter, interventional TOMBOLA trial (NCT04138628), were shared in an oral...

Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that multiple abstracts will be presented at the 40 th Annual European Association of Urology Congress (EAU25) demonstrating the clinical performance and utility of its Decipher tests in prostate and bladder cancer. Additionally, independent performance data supporting the company’s minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer will be unveiled from a large, multicenter...

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. “I’m incredibly proud of what our team accomplished in 2024,” said Marc Stapley, Veracyte’s chief executive officer. “We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant opportunities for Decipher and Afirma...

Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 46 th Annual Institutional Investors Conference – Orlando, FL Presentation on March 5 th at 9:50 a.m. Eastern Time Leerink Partners Global Healthcare Conference – Miami, FL Fireside Chat on March 11 th at 8:40 a.m. Eastern Time Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer. Presented findings also show that the company’s Decipher GRID (Genomic Resource for Intelligent Discovery) research tool is enabling new data-based insights...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU). The findings demonstrate the market leadership of its Decipher tests in better informing treatment decisions for patients with prostate and bladder cancers, compared to standard approaches, and in helping to drive innovation that will inform the future of urologic cancer care. The conference will take...

Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data that reinforce the ability of its Decipher Bladder Genomic Subtyping Classifier to help improve staging for patients with bladder cancer, based on their tumors’ molecular subtype. The findings, published in European Urology Open Science , show that the test can help clinicians better determine which patients are more likely to harbor more aggressive disease than suggested by their initial clinical...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2024 after the close of market on Monday, February 24, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company’s website and will be available via the following...

Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the only gene expression test to be included in version 1 of the 2025 NCCN * Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) as part of the updated “Advanced Tools” table located in the Principles of Risk Stratification and Biomarkers section (PROS-H) . “The Decipher Prostate test’s performance and clinical utility have been...

Veracyte, Inc . (Nasdaq: VCYT) announced that new data published in JCO Precision Oncology suggest that gene expression signatures derived from the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database may help advance understanding of the genomic drivers impacting patient response to treatment for recurrent prostate cancer. The findings, from the Phase 2 STREAM study, suggest the potential to use transcriptomic signatures to identify patients in this setting who may...

Veracyte, Inc . (Nasdaq: VCYT) announced that its South San Francisco and San Diego offices have been named top workplaces. Veracyte’s South San Francisco location has been awarded a Top Bay Area Workplaces 2023 honor by the San Francisco Chronicle , in partnership with Energage, LLC. This is Veracyte’s tenth consecutive year receiving this honor. Additionally, Veracyte’s San Diego office has received its inaugural Best Places to Work in San Diego award by the San Diego Business Journal...

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2023. “We delivered outstanding second quarter results, with revenue and test volume that exceeded our expectations. We also generated a record $17 million in cash from operations this quarter, driven by our exceptional top-line performance and strong cash collections,” said Marc Stapley, Veracyte’s chief executive officer. “The compelling clinical data we shared this quarter...

Veracyte, Inc . (Nasdaq: VCYT) announced the publication of a large, real-world study reinforcing the Decipher Prostate Genomic Classifier’s ability to guide personalized treatment approaches for men with prostate cancer. The study utilized data from the first linkage of prostate cancer cases reported by central cancer registries participating in the Surveillance, Epidemiology, and End Results (SEER) Program, with Decipher test results. SEER is a population-based cancer registry supported by...

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2023 after the close of market on Tuesday, August 8, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/iwy5xkbf...

Veracyte, Inc . (Nasdaq: VCYT) announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology. In addition, findings from an analytical validity study presented at the meeting show that the Afirma TERT promoter mutation test performs with high analytical sensitivity and specificity....

Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting new data on the company’s Afirma test and capabilities will be presented at ENDO 2023, the annual meeting of The Endocrine Society, which is taking place June 15-18 in Chicago, Ill. Additionally, Veracyte’s medical director of Endocrinology, Joshua Klopper, M.D., will participate in a symposium panel discussion on the advantages of various molecular testing approaches to help personalize and improve care for...

Veracyte, Inc . (Nasdaq: VCYT) announced that new data to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrate the ability of the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database to enable novel molecular insights into prostate cancer. The findings, from three separate studies, may ultimately help inform more personalized treatment for patients with prostate cancer. “The Decipher GRID-based data that will be shared at...

Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C. Findings from two posters suggest that the Envisia Genomic Classifier helps improve diagnosis and changes treatment decisions for patients with...

Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences: William Blair 43 rd Annual Growth Stock Conference – Chicago, IL Presentation on June 6 th at 9:40 a.m. Eastern Time Goldman Sachs 44 th Annual Global Healthcare Conference – Dana Point, CA Fireside Chat on June 13 th at 6:20 p.m. Eastern Time Live audio webcasts of the company’s presentations will be...

Veracyte, Inc. (Nasdaq: VCYT) announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease. The findings are from EMIT, a prospective, multi-year, population-based study in Norway that is investigating the impact of molecular testing – specifically, the Prosigna test – on breast cancer care and outcomes....